Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study-Reference-Cited by-同舟云学术

Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study

Published:2016-10 Issue: Volume:96 Page:165-170
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Morgia Giuseppe,Russo Giorgio Ivan^ORCID,Tubaro Andrea,Bortolus Roberto,Randone Donato,Gabriele Pietro,Trippa Fabio,Zattoni Filiberto,Porena Massimo,Mirone Vincenzo,Serni Sergio,Del Nero Alberto,Lay Giancarlo,Ricardi Umberto,Rocco Francesco,Terrone Carlo,Pagliarulo Arcangelo,Ludovico Giuseppe,Vespasiani Giuseppe,Brausi Maurizio,Simeone Claudio,Novella Giovanni,Carmignani Giorgio,Leonardi Rosario,Pinnarò Paola,De Paula Ugo,Corvò Renzo,Tenaglia Raffaele,Siracusano Salvatore,Mantini Giovanna,Gontero Paolo,Savoca Gianfranco,Ficarra Vincenzo

Funder

Takeda Pharmaceutical Company

Publisher

Elsevier BV

Subject

Urology

Reference23 articles.

1. Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy;James;Urology,2014

2. Long-term impact of androgen-deprivation therapy on cardiovascular morbidity after radiotherapy for clinically localized prostate cancer;Kohutek;Urology,2016

3. Osteoporosis management program decreases incidence of hip fracture in patients with prostate cancer receiving androgen deprivation therapy;Zhumkhawala;Urology,2013

4. Contemporary role of androgen deprivation therapy for prostate cancer;Pagliarulo;Eur Urol,2012

5. Clinical practice guidelines on prostate cancer: a critical appraisal;Gupta;J Urol,2015

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS);Clinical Genitourinary Cancer;2023-10

2. Appropriateness and complications of androgen deprivation therapy for prostate cancer: Can we do better? A retrospective observational analysis from a referral center;Urologia Journal;2023-01-26

3. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review;Cureus;2022-06-22

4. Association between medical androgen deprivation therapy and long‐term cardiovascular disease and all‐cause mortality in nonmetastatic prostate cancer;International Journal of Cancer;2022-05-17

5. Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers;Research and Reports in Urology;2022-03